Loading…
← CockpitCompetitor Analysis › 688566.SS Jiangsu Jibeier Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Jiangsu Jibeier Pharmaceutical Co. Ltd. Class A688566.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 76
Mkt cap
$727M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$9.62M
20-day average traded
Fwd P/E
11.2×
forward earnings
ROIC−WACC
+4.7 pp
WACC 8.3%
Hurdle
-5 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥24.32
1D-3.6%
1W-7.7%
1M-8.9%
3M-7.6%
6M-9.4%
YTD-18.5%
1Y-25.9%
ATR %3.4%
52w lowhigh27.6% off high

What Jiangsu Jibeier Pharmaceutical does

Employees: 1,354

Jiangsu Jibeier Pharmaceutical at a glance

Size Jiangsu Jibeier Pharmaceutical (688566.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $727M, the 2810th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥24.32 on 18 Nov 2026.

Performance Over six months the shares fell 9.4%, against -7.0% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 8.2% over the last twelve months (peer median +0.7%); the operating margin is 26.2% (peer median 9.6%).

Valuation It trades at 11.2× forward earnings against a peer median of 16.1× (3rd cheapest of 8).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.7 points above its cost of capital (8.3% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 94688566.SS 93
Six months, rebased to 100: Jiangsu Jibeier Pharmaceutical against the median of its 20 peers (local-currency closes).

Jiangsu Jibeier Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.04BCN¥954MCN¥886MCN¥853MCN¥648M
Revenue growth—+8%+4%+32%—
Gross profitCN¥937MCN¥842MCN¥787MCN¥754MCN¥567M
EBITDAn/aCN¥266MCN¥300MCN¥243MCN¥170M
Net incomeCN¥241MCN¥262MCN¥219MCN¥219MCN¥155M
Free cash flowCN¥223MCN¥137MCN¥46.3M-CN¥193M-CN¥130M
Capital expenditureCN¥84.0MCN¥115MCN¥175MCN¥357MCN¥293M
Total debtCN¥7.05MCN¥18.7MCN¥20.8MCN¥9.91MCN¥0

Quarterly statements and history in the cockpit →

Jiangsu Jibeier Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%-10%0%+10%600530688799SGMT6039982186300705057045346004792171002907600829002424NVCT3001LXRX4985000915BLISSGVS688566.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Jibeier Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%20×40×688799603998218630070545344985000915688566.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Jibeier Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%600530603998218630070560047900290760082900242430014985002390BLISSGVS688566.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiangsu Jibeier Pharmaceutical is the large dot.

Jiangsu Jibeier Pharmaceutical competitors and peer comparison

How Jiangsu Jibeier Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Jibeier Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688566.SSPeer medianRank in peer set
1-month return-8.9%-1.9%6th lowest of 21
6-month return-9.4%-7.0%10th lowest of 21
Distance from 52-week high-27.6%-34.0%7th highest of 21
Revenue growth (TTM)+8.2%+0.7%6th highest of 19
Operating margin26.2%9.6%2nd highest of 19
Forward P/E11.2×16.1×3rd cheapest of 8
Growth the price implies (Req g, 7 yrs)5.9%-0.7%5th most demanding of 13
Growth delivered (Del g)+11.3%+0.2%2nd highest of 13
Hurdle (Req g minus delivered)-5.4 pp-0.8 pp4th least demanding of 13
ROIC minus cost of capital+4.7 pp+0.2 pp5th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%16.7×-2.0%+26.1%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%n/a-2.1%0.0%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%n/an/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%n/a9.4%-1.4%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%n/a13.5%-0.2%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%

Questions

Which companies are Jiangsu Jibeier Pharmaceutical's closest peers?
The cockpit's peer set: Shanghai Jiaoda Onlly (600530.SS), Hunan Warrant Pharmaceutical (688799.SS), Sagimet Biosciences (SGMT), Hunan Fangsheng Pharmaceutical (603998.SS), Luye Pharma (2186.HK), Hunan Jiudian Pharmaceutical (300705.SZ), China Traditional Chinese Medicine (0570.HK), Mochida Pharmaceutical (4534.T).
Is Jiangsu Jibeier Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 11.2× against a peer median of 16.1×, 3rd cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Jiangsu Jibeier Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -9.4% against -7.0% for the median peer; over one year -25.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.